At a glance
- Originator Merck & Co
- Class Antihyperglycaemics; Pyridines
- Mechanism of Action Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 11 May 1999 New profile
- 11 May 1999 Preclinical development for Diabetes mellitus in USA (Unknown route)